Authors
Fannie Darlot, Cécile Moro, Nabil El Massri, Claude Chabrol, Daniel M Johnstone, Florian Reinhart, Diane Agay, Napoleon Torres, Dhaïf Bekha, Vincent Auboiroux, Thomas Costecalde, Cassandra L Peoples, Helena DT Anastascio, Victoria E Shaw, Jonathan Stone, John Mitrofanis, Alim‐Louis Benabid
Publication date
2016/1
Journal
Annals of neurology
Volume
79
Issue
1
Pages
59-75
Description
Objective
To examine whether near‐infrared light (NIr) treatment reduces clinical signs and/or offers neuroprotection in a subacute 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) monkey model of Parkinson disease.
Methods
We implanted an optical fiber device that delivered NIr (670nm) to the midbrain of macaque monkeys, close to the substantia nigra of both sides. MPTP injections (1.5–2.1mg/kg) were made over a 5‐ to 7‐day period, during which time the NIr device was turned on. This was then followed by a 3‐week survival period. Monkeys were evaluated clinically (eg, posture, bradykinesia) and behaviorally (open field test), and their brains were processed for immunohistochemistry and stereology.
Results
All monkeys in the MPTP group developed severe clinical and behavioral impairment (mean clinical scores = 21–34; n = 11). By contrast, the MPTP‐NIr group developed much less …
Scholar articles
F Darlot, C Moro, N El Massri, C Chabrol… - Annals of neurology, 2016